surpass cvot tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide

From a practical point of view, our results suggested that 2 g/d of LCR supplementation improved muscle strength and anaerobic performance while decreasing post-exercise BL levels and attenuating exercise-induced oxidative stress markers in resistance-trained athletes

Its not emptiness, and certainly nothing is broken

Maintenance and prevention protocol Lower-dose combination approaches support ongoing tissue health and injury prevention in active individuals with chronic tissue demands

Peptides, essentially short proteins, havent been in medicine quite as long, but for nearly a century, theyve played an important role